TRENBOLONE ENANTHATE 1 ml/ 200 mg
Formula: Cl 8H2202 MolecularWeight: 270.37 gm/mol Active life: 8 days Detection time: 5 months Anabolic/Androgenic ratio: 500/500
Trenbolone Enanthate is a steroid compound that is described chemically as 17(3- Hyd rox Aestra-4,9,1 l-trien-3-one enanthate.
TREN 200® is a sterile solution of 200 mg/ml Trenbolone Enanthate, Miglyol 840, Ethyl oleate. Benzyl benzoate. Benzyl alcohol.
Trenbolone Enanthate has been used as a prolong acting anabolic agent in veterinary practice.
TREN 200® is an oil based solution of Trenbolone Enanthate for intramuscular injection. Trenbolone is an anabolic steroid with significant anabolic and androgenic effects.The enanthate ester produces an initial serum response within 24-hours with duration of action of 7 to 10 days. Trenbolone promotes significant increases in strength, muscle anabolism, appetite, and aggression and has been demonstrated to reduce body fat.
TREN 200® is a prolong acting injectable steroid with a great effect on protein metabolism. Trenbolone is one of the best effective anabolic compounds, promoting protein synthesis, as well as creating a positive nitrogen balance. It is an appetite stimulant and improves the conversion of proteins. In laboratory tests, it has been demonstrated that Trenbolone increases protein and decreases fat deposition. It has proven to be an excellent product for promoting size and strength in the presence of adequate protein and calories, promotes body tissue building processes, and can reverse catabolism.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle- stimulating hormone (FSH).
Trenbolone binds strongly to the androgen receptor and its action is generally considered to derive therefrom. It produces significant anabolism even during periods of limited caloric restriction. The literature offers conflicting reports of the susceptibility of Trenbolone to aromatize into estrogen or reduce to a dihydrotestosterone derivative. Rat studies have suggested that Trenbolone may exert effects typically associated with dihydrotestosterone through a non-DHT pathway potentially with direct receptor action. It has been suggested that Trenbolone may reduce cortisol production through an indeterminate pathway of activity upon glucocorticoid receptors.
Trenbolone has been demonstrated to promote muscle growth, appetite, aggression, and the production of red blood cells through the production of erythropoietic stimulating factor. Trenbolone is suspected of selective binding of the progesterone receptor potentially acting as both an agonist and an antagonist. It has been suggested that Trenbolone is capable of binding to the prolactin receptor. Thus serum progesterone and serum prolactin levels should be monitored during treatment and if elevated anti-progesterone and anti-prolactin agents should be considered.
Males: Trenbolone use may be indicated in patients where substantial weight gain and increases in musculature are required for patient health after substantial losses of body mass especially in instances where caloric intake is limited and other anabolic therapies have previously failed. The physician and patient must consider the risks of therapy versus the potential benefits.